Completed PHASE2 INTERVENTIONAL 10-arm NCT02430194

Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2) (LOWR-2)

An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With Ritonavir-Boosting +/- Peginterferon Alfa-2a in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-2)

Sponsor: Ankara University

Conditions Chronic Hepatitis D Infection

Interventions Pegylated interferon-alfa-2a lonafarnib ritonavir

Updated 9 times since 2017 Last updated: Mar 1, 2023 Started: Dec 31, 2014 Primary completion: Apr 18, 2017 Completion: Jun 15, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02430194, this PHASE2 trial focuses on Chronic Hepatitis D Infection and remains completed. Sponsored by Ankara University, it has been updated 9 times since 2014, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2023 — Jul 2024 [monthly]

Completed PHASE2
Mar 2023 — Apr 2023 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Mar 2023 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Sep 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Jan 2017 — Sep 2017 [monthly]

Recruiting PHASE2

First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ankara University
Eiger BioPharmaceuticals

Data source: Eiger BioPharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ankara, Turkey (Türkiye)